Peptides are increasingly entering drug development pathways as potential active pharmaceutical ingredients due to their large chemical space, relative ease of synthesis, ready availability of low cost starting materials and general low toxicity. As a result, approximately 60 peptide-based drugs have been approved by the FDA, 140 peptidic drugs are currently under evaluation in clinical trials and a further 500 peptides are in development. Success stories include the prostate cancer drug Lupron™ from Abbott Laboratories, with global sales of more than US$2.3 billion in 2011. Understandably, research into the area of new peptide drugs is at an all-time high.
With synthesis visualization software, higher loading capacity in purification, and effective evaporation technology, Biotage has developed a suite of technology to support the whole peptide workflow.
Download the white paper below (PPS468)
Update on Biotage’s COVID-19 Response Plan
Smarter Sample Preparation for Environmental Challenges
How does Biotage Act in the Corona Virus Situation?
Sample Preparation Techniques for Synthetic Benzodiazepines
Good Laboratory Practices Software Upgrade for Biotage® Extrahera™